Bovine Mastitis Market - Historic Data (2019-2024), Global Trends 2025, Growth Forecasts 2037
Bovine Mastitis Market in 2025 is estimated at USD 2.45 billion. The global market size was over USD 2.31 billion in 2024 and is anticipated to witness a CAGR of around 7.5%, crossing USD 5.91 billion revenue by 2037. North America is expected to hit USD 2.01 billion by 2037, supported by the rising prevalence of bovine mastitis and dairy industry expansion.
The growth of the market can be attributed to the worldwide rapid growing prevalence of bovine mastitis in cattle. For instance, as of now around 32% of Saharan countries have occurrences of Bovine Mastitis (BM). Mastitis is however common in Asian countries as well, with a prevalence of more than 54%. Further, the growing prevalence of bovine mastitis infections during the dry season, along with the improved benefits of non-antibiotic intramammary products such as Teat Sealants in deterring intramammary infections during the dry season, are predicted to drive the market expansion.
In addition to these factors that are believed to fuel the market growth of bovine mastitis include the surge in research and development activities for developing advanced treatment to treat bovine mastitis more effectively, followed by the poor hygiene rate in cattle, injury to the mammary section, as well as expanding awareness in the dairy farmers about the treatment of Bovine Mastitis (BM) in their cattle. Bovine Mastitis has emerged as a major concern in the dairy industry around the world, and dairy farmers have been facing significant financial losses as the incidence of this disease in cattle increases year after year. The significantly increasing burden of mastitis throughout the world is fueling up demand for the bovine mastitis market. For instance, until the first quarter of 2022, the most expensive charges associated with mastitis in Germany were milk wastage (varying from 28 to 51%, with an average rate of 36%) and rejected milk (varying from 12 to 32%, with an average price of 21%). Moreover, the prevalence of subclinical mastitis was estimated to cost approximately USD 810,000 per year in Colombian cattle farms, with milk production losses ranging from 1.5 to 12.8% per farm.
Bovine Mastitis Sector: Growth Drivers and Challenges
Growth Drivers
-
Enormous Surge in Dairy Production Across the Globe – Dairy production is directly connected with dairying, which is also known as dairy farming. It is an agricultural branch that includes the breeding, raising, and use of dairy animals, primarily cows, for the production of milk and the various dairy products made from it. Henceforth, the increase in dairy products has an intense impact on the bovine’s health and hygiene which is leading the market growth over the forecast period. For instance, in 2020, the world produced nearly 907 million tons of milk, an increase of 3% from 2019.
-
Worldwide Rise in the Number of Farm Cattle – For instance, the global cattle population was anticipated to reach around 1.5 billion head in 2022, slightly higher compared to 998 million in 2021.
-
Globally Escalating Consumption of Milk – For instance, India consumed the foremost cow milk in the world in 2021, consuming approximately 85 million metric tons. Whereas, the European Union consumed the most milk, with 24 million metric tons.
-
Rising Count of Veterinary Hospitals and Polyclinics – For instance, during the fiscal year 2021, there were approximately 12,070 veterinary hospitals and polyclinics in India. Moreover, approximately 67,000 veterinary institutions, as well as numerous aid centers and dispensaries, were noticeable across the country that year.
-
Global Rise in Research and Development Investment – As per the report of the UNESCO Institute for Statistics, with an average annual growth rate of 4.7% over the past ten years, global R&D investment has risen significantly from 2010-2020. Globally, from 1.61% in 2010 to 1.93% in 2020, the percentage of global GDP invested in research and development has increased exponentially.
Challenges
-
Increase in Antibiotic Resistance Pathogen – The prolonged use of antibiotics to treat Bovine Mastitis led to a surge in antimicrobial resistance in the pathogens that cause this infectious disease in cattle. Subsequently, the increase in multi-resistant strains reduces the effectiveness of the antibiotics that are associated with the treatment. Thus, this factor is estimated to hamper the market’s growth during the forecast period.
- Lack of Awareness Regarding Bovine Mastitis
- Inadequate Accessibility of Drugs
Bovine Mastitis Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.5% |
|
Base Year Market Size (2024) |
USD 2.31 billion |
|
Forecast Year Market Size (2037) |
USD 5.91 billion |
|
Regional Scope |
|
Bovine Mastitis Segmentation
End-user (Veterinary Centers, Hospitals, Clinics, On-Site Treatment)
The global bovine mastitis market is segmented and analyzed for demand and supply by end-user into veterinary centers, hospitals, clinics, on-site treatment, and others. Out of these, the on-site treatment segment is estimated to grow at a significant rate over the forecast period. The growth of the segment can be attributed to the significant growth in the dairy farm industry across the globe, followed by the surge in the number of veterinarians across the globe. For instance, there are presently over 48,700 veterinarians working in the United States.
Product (Antibiotics, Pain Killers, Vaccines)
The global bovine mastitis market is also segmented and analyzed for demand and supply by-products into antibiotics, painkillers, vaccines, and others. Amongst these four segments, the antibiotics segment is expected to garner a significant share. The significant growth in this segment is backed by the very limited existence of other class of drugs to treat this disease, therefore a huge count of dairy farmers has been relying on and using antibiotics for effectively controlling and treating mastitis in their cattle. On the other hand, the painkillers segment is estimated to garner a notable share in the market, as painkillers are mostly used to reduce pain in cattle as a result of mastitis problems. The inclusion of a pain killer such as meloxicam, in normal antibiotic therapy for bovine mastitis increases the rate of conceiving, which later improves the reproduction rate and adds up to positive economic advantages for the farmers.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Product |
|
|
By Route of Administration |
|
|
By Therapy |
|
|
By End-User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportBovine Mastitis Industry - Regional Synopsis
North American Market Forecast
North America industry is expected to account for largest revenue share of 34% by 2037. The growth of the market can be attributed majorly to the massively increasing prevalence of bovine mastitis in cattle, and the significantly expanding dairy industry in the region. For instance, in 2022, the number of dairy farm businesses in the United States has increased by approximately 34,950 farms. Further, the presence of major key players who are providing a wide range of treatment of this disease, along with a surge in animal healthcare infrastructure which is paving the way to make the farmers more aware for animal health, are also anticipated to contribute to the market growth in the region. In addition, rising investment in research and development in the effective treatment of mastitis is another sign which is estimated to drive the market growth further throughout the forecast period in the region.
APAC Market Statistics
The Asia Pacific bovine mastitis market is anticipated to display the fastest market growth by the end of 2037. The growth of the market can be attributed to the large number of cattle in the region, coupled with the rising cases of mastitis disease in cattle. Additionally, the surging count of dairy farms in this region is another key factor that is fueling the growth of the market during the projected time frame.
Companies Dominating the Bovine Mastitis Landscape
- Boehringer Ingelheim International GmbH
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Zoetis Inc.
- Merck & Co., Inc.
- Ceva Santé Animale
- Nimrod Veterinary Products Ltd
- Bayer AG
- ImmuCell Corporation
- West Way Health
- Neogen Corporation
- Forte Healthcare Ltd.
In the News
-
Boehringer Ingelheim International GmbH announced that the Clinical and Laboratory Standards Institute (CLSI) approved revised interpretive criteria for testing the susceptibility to Ubrolexin, an intramammary treatment for mastitis in lactating dairy cows that combines kanamycin and cefalexin.
-
Neogen Corporation announced a full range of dairy hygiene products, including teat dips and sprays, bulk tank cleaners, hoof care, and dairy cleaning products. Designed to reduce the transmission of mastitis-causing bacteria to dairy animals and provide high emollient content for teat protection and conditioning, the range of teat dips and sprays is suitable for pre-milking, pre/post-milking, and post-milking.
Author Credits: Radhika Pawar
- Report ID: 4647
- Published Date: Apr 23, 2025
- Report Format: PDF, PPT
